Quantification of metamorphopsia using the MacuFlow test before and after vitreoretinal surgery.
This pilot study evaluated the clinical utility of the MacuFlow software in measuring metamorphopsia prior to and following surgery in patients with vitreoretinal diseases. Four patients with vitreoretinal disorders causing metamorphopsia were included in this pilot study. Visual acuity (VA), optical coherence tomography and MacuFlow scores were recorded prior to and following surgical intervention. The mean preoperative VA was 0.59 ± 0.09 logMAR, central macular thickness 491.2 ± 41.3 µm and calculated macular volume 8.99 ±1.47 mm(3). These parameters improved postoperatively to a mean VA of 0.30 ± 0.22 logMAR, central macular thickness of 372.8 ± 85.4 µm and macular volume of 7.94 ± 1.34 mm(3) but did not reach statistical significance. The mean preoperative MacuFlow score was 14.02 ± 8.21, which significantly improved postoperatively to 5.4 ± 3.13 (p = 0.045). This is the first study to demonstrate the clinical utility of MacuFlow for the quantification of metamorphopsia and its improvement or resolution following surgery. This simple method may be a valuable addition for the clinical assessment and monitoring of patients with retinal diseases causing metamorphopsia.